BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 16550003)

  • 1. In-vitro schedule-dependent interaction between oxaliplatin and 5-fluorouracil in human gastric cancer cell lines.
    Qin B; Tanaka R; Shibata Y; Arita S; Ariyama H; Kusaba H; Baba E; Harada M; Nakano S
    Anticancer Drugs; 2006 Apr; 17(4):445-53. PubMed ID: 16550003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro schedule-dependent interaction between paclitaxel and oxaliplatin in human cancer cell lines.
    Tanaka R; Ariyama H; Qin B; Takii Y; Baba E; Mitsugi K; Harada M; Nakano S
    Cancer Chemother Pharmacol; 2005 Jun; 55(6):595-601. PubMed ID: 15731917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro sequence-dependent interaction between nedaplatin and paclitaxel in human cancer cell lines.
    Tanaka R; Takii Y; Shibata Y; Ariyama H; Qin B; Baba E; Kusaba H; Mitsugi K; Harada M; Nakano S
    Cancer Chemother Pharmacol; 2005 Sep; 56(3):279-85. PubMed ID: 15875187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Schedule-dependent synergistic interaction between gemcitabine and oxaliplatin in human gallbladder adenocarcinoma cell lines.
    Makiyama A; Qin B; Uchino K; Shibata Y; Arita S; Isobe T; Hirano G; Kusaba H; Baba E; Akashi K; Nakano S
    Anticancer Drugs; 2009 Feb; 20(2):123-30. PubMed ID: 19209029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells.
    Schwartz GK; Farsi K; Maslak P; Kelsen DP; Spriggs D
    Clin Cancer Res; 1997 Sep; 3(9):1467-72. PubMed ID: 9815832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic interaction between oxaliplatin and SN-38 in human gastric cancer cell lines in vitro.
    Tanaka R; Ariyama H; Qin B; Shibata Y; Takii Y; Kusaba H; Baba E; Mitsugi K; Harada M; Nakano S
    Oncol Rep; 2005 Sep; 14(3):683-8. PubMed ID: 16077975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of in vitro cytotoxicity of oxaliplatin and 5-fluorouracil in human colon cancer cell lines: combination versus sequential exposure.
    Failli A; Consolini R; Legitimo A; Orsini G; Romanini A; Spisni R; Castagna M; Miccoli P
    J Biol Regul Homeost Agents; 2011; 25(4):575-88. PubMed ID: 22217990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of 5-fluouracil combined with sulfasalazine on human pancreatic carcinoma cell line BxPC-3 proliferation and apoptosis in vitro.
    Huang Z; Guo KJ; Guo RX; He SG
    Hepatobiliary Pancreat Dis Int; 2007 Jun; 6(3):312-20. PubMed ID: 17548258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-tumor activity of heptaplatin in combination with 5-fluorouracil or paclitaxel against human head and neck cancer cells in vitro.
    Lee JW; Park JK; Lee SH; Kim SY; Cho YB; Kuh HJ
    Anticancer Drugs; 2006 Apr; 17(4):377-84. PubMed ID: 16549994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell cycle arrest and apoptosis induced by oxaliplatin (L-OHP) on four human cancer cell lines.
    William-Faltaos S; Rouillard D; Lechat P; Bastian G
    Anticancer Res; 2006; 26(3A):2093-9. PubMed ID: 16827150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intermittent FLDP: 24-h infusion of 5-FU on days 1, 3 and 5 combined with low-dose cisplatin on days 1-5 for gastric cancer, and its pharmacologic and kinetic rationale.
    Terashima M; Irinoda T; Kawamura H; Takagane A; Abe K; Oyama K; Fujiwara H; Saito K; Gotoh M; Shirasaka T
    Cancer Chemother Pharmacol; 2003 Mar; 51(3):240-6. PubMed ID: 12655443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The evaluation of gastric cancer sensitivity to 5-FU/CDDP in terms of induction of apoptosis: time- and p53 expression-dependency of anti-cancer drugs.
    Matsuhashi N; Saio M; Matsuo A; Sugiyama Y; Saji S
    Oncol Rep; 2005 Sep; 14(3):609-15. PubMed ID: 16077963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequence-dependent administration of 5-fluorouracil maintains methotrexate antineoplastic activity in human estrogen-negative breast cancer and protects against methotrexate cytotoxicity in human bone marrow.
    Das JR; Fryar-Tita EB; Zhou Y; Green S; Southerland WM; Bowen D
    Anticancer Res; 2007; 27(6B):3791-9. PubMed ID: 18225534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell cycle arrest by oxaliplatin on cancer cells.
    William-Faltaos S; Rouillard D; Lechat P; Bastian G
    Fundam Clin Pharmacol; 2007 Apr; 21(2):165-72. PubMed ID: 17391289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identifying mechanisms of chronotolerance and chronoefficacy for the anticancer drugs 5-fluorouracil and oxaliplatin by computational modeling.
    Altinok A; Lévi F; Goldbeter A
    Eur J Pharm Sci; 2009 Jan; 36(1):20-38. PubMed ID: 19041394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment schedule-dependent effect of 5-fluorouracil and platinum derivatives in colorectal cancer cells.
    Takara K; Fujita M; Minegaki T; Yamamoto K; Takahashi M; Yokoyama T; Okumura K
    Eur J Pharm Sci; 2012 Feb; 45(3):272-81. PubMed ID: 22155546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined effect of 5-fluorouracil and carboplatin against human gastric cancer cell lines in vitro and in vivo.
    Saikawa Y; Kubota T; Kuo TH; Tanino H; Kase S; Furukawa T; Watanabe M; Ishibiki K; Kitajima M; Hoffman RM
    Anticancer Res; 1994; 14(2A):461-4. PubMed ID: 8017848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic antitumour effect of raltitrexed and 5-fluorouracil plus folinic acid combination in human cancer cells.
    Avallone A; Di Gennaro E; Bruzzese F; Laus G; Delrio P; Caraglia M; Pepe S; Comella P; Budillon A
    Anticancer Drugs; 2007 Aug; 18(7):781-91. PubMed ID: 17581300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cells.
    Temmink OH; Hoebe EK; van der Born K; Ackland SP; Fukushima M; Peters GJ
    Br J Cancer; 2007 Jan; 96(2):231-40. PubMed ID: 17242697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin.
    Petrioli R; Pascucci A; Francini E; Marsili S; Sciandivasci A; Tassi R; Civitelli S; Tanzini G; Lorenzi M; Francini G
    Cancer Chemother Pharmacol; 2008 Jan; 61(1):105-11. PubMed ID: 17429632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.